Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
19 janv. 2021 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in...
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
14 janv. 2021 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
11 janv. 2021 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics...
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 janv. 2021 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Annual...
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
21 déc. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
First gene therapy to receive full EU marketing authorization for eligible MLD patients One-time treatment with Libmeldy has been shown to preserve motor and cognitive function Achievement shared...
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
08 déc. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept...
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
24 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D....
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
19 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET
12 nov. 2020 16h01 HE
|
Orchard Therapeutics (Europe) Limited
First look at preclinical data in frontotemporal dementia with progranulin mutations (GRN-FTD) and new amyotrophic lateral sclerosis (ALS) program NOD2 mutation revealed as Crohn’s disease (CD)...
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit
09 nov. 2020 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene...